Trilaciclib combined with topotecan as second-line treatment for extensive-stage small-cell lung cancer:a case report and literature review
YUAN Jing
LU Wei-ping
XIAO Guo-dong
FAN Hui-jie
Abstract：Small cell lung cancer(SCLC)is characterized by a high degree of malignancy,with poor prognosis and high-growth fraction.About two-thirds of patients have developed distant metastasis at the time of diagnosis with rapid disease progression and high recurrence rates.Currently,topotecan-based chemotherapy remains the standard second-line treatment of SCLC with unfavorable disease remission,and less than one-fourth of patients have benefited from its efficacy.Chemotherapy-induced myelosuppression(CIM)is the most common toxicity in cancer chemotherapy,and severe CIM will reduce the dose intensity and anti-tumor efficacy of chemotherapy.Trilaciclib is a short-acting intravenous cyclin-dependent kinase 4/6(CDK4/6)inhibitor administered prior to chemotherapy to preserve hematopoietic stem and progenitor cells and immune system function during chemotherapy,which has been approved by NMPA for prevention of CIM in SCLC in July 2022.Previous results showed that trilaciclib yielded favorable bone marrow protection during chemotherapy,but its anti-tumor effects in second-line treatment of SCLC have not been determined.This paper reports a case of a patient with advanced small-cell lung cancer with multiple metastases who obtained progression-free survival time of more than 1 year using trilaciclib combined with topotecan as second-line treatment.
Keywords：small-cell lung cancerchemotherapymyelosuppressiontrilaciclib
Publication Date：2023-12-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 2360-2365 )